Thanks to Emma for updating us on their recent episodes:
Episode 07: A Transcriptional Switch Governs Fibroblast Activation in Heart Disease
In Episode 07 we discuss BET inhibitors and fibroblast activation with Michael Alexanian @m_alexanian a Postdoctoral researcher at Gladstone Institutes @Gladstoneinst. Michael explains how BET inhibitors have emerged as a potent tool to reversibly interfere with enhancer to promoter signalling. This has been shown to ameliorate heart failure in mouse models and is a highly translatable method of preventing heart failure in humans. We also discuss two powerful tools, scRNASeq and scATAC-seq, and how they were used to investigate transcription and epigenetic changes of activated fibroblasts. We then discuss the impact of downstream targets and the impact on drug discovery.
Episode 08 Identification of ACE2 modifiers by CRISPR screening
In Episode 08 we discuss high throughput CRISPR/Cas9 screening and how these have been adapted to investigate treatments for COVID-19 with Emily Sherman and Brian Emmer (@brianemmer), a post doctoral researcher and recent PI at University of Michigan. We cover details on how to conduct a high throughput CRISPR/Cas9 screen, the exciting advances in NextGen sequencing as well as what it’s like to set up your own lab while working as a clinician in a hospital during a pandemic. We also speak to Emily about her transition from academia to industry and our usual discussion about the benefits of preprints.
These episodes were produced by Emma Wilson and edited by Jonny Coates and John D Howard.